12.07.2015 Views

DOULEUR ET PERSONNE ÂGÉE - Institut upsa de la douleur

DOULEUR ET PERSONNE ÂGÉE - Institut upsa de la douleur

DOULEUR ET PERSONNE ÂGÉE - Institut upsa de la douleur

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

63. Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in thetreatment of diabetic peripheral neuropathic pain in ol<strong>de</strong>r patients. Curr Drug Saf2009; 4:22-29.64. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics ofduloxetine in women. Br J Clin Pharmacol 2004; 57:54-61.65. Ball SE, Ahern D, Scantina J, Kao J. Ven<strong>la</strong>faxine: in vitro inhibition of CYP2D6 <strong>de</strong>pendingimipramine and <strong>de</strong>sipramine metabolism: comparative studies with selected SSRI’s,and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br J Clin Pharmacol1997; 42:619-626.66. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single and multiple-dosebupropion in el<strong>de</strong>rly patients with <strong>de</strong>pression. J Clin Pharmacol 1995; 35:876-884.67. Kerse N, Flicker L, Pfaff JJ, et al. Falls, <strong>de</strong>pression and anti<strong>de</strong>pressants in <strong>la</strong>ter life: a <strong>la</strong>rgeprimary care appraisal. PLoS ONE 2008; 3:e2423.68. Gore M, Sadosky A, Leslie D, Sheehan AH. Selecting an appropriate medication fortreating neuropathic pain in patients with diabetes: a study using the U.K. andGermany Mediplus Databases. Pain Pract 2008; 8:253-262.69. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug loadand yet add nee<strong>de</strong>d drugs in the el<strong>de</strong>rly? Proposal of a new drug c<strong>la</strong>ssification: fit forthe aged. J Am Geriatr Soc 2009; 57:560-561.70. Sharma U, McCarberg W, Young JH, LaMoreaux L. Pregabalin treatment for neuropathicpain: efficacy and tolerability in ol<strong>de</strong>r people. J Pain 2005; 3(Suppl. 1):S29.71. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety ofpregabalin in el<strong>de</strong>rly people with generalised anxiety disor<strong>de</strong>r. Br J Psychiat 2008;193:389-394.72. May TW, Rambeck B, Neb R, Jürgens U. Serum concentrations of pregabalin in patientswith epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2007;29:789-794.73. Cutler RB, Fishbain DA, Rosomoff RS, Rosomoff HL. Outcomes in treatment of pain ingeriatric and younger age groups. Arch Phys Med Rehabil 1994; 75:457-464.74. Lussier D, Bachand G, Haché D, Rivard MJ, Inglis G. An Interdisciplinary Geriatric PainClinic. Abstracts of the 12th World Congress on Pain. Poster presentation at the 12thWorld Congress on Pain (International Association for the Study of Pain), G<strong>la</strong>sgow, UK(August 2008).75. Middaugh SJ, Levin RB, Kee WG, Barchiesi FD, Roberts JM. Chronic pain: its treatmentin geriatric and younger patients. Arch Phys Med Rehabil 1988; 69:1021-1025.SPÉCIFICITÉS DE LA PRISE EN CHARGE ANTALGIQUE DE LA <strong>DOULEUR</strong> CHEZ LA <strong>PERSONNE</strong> ÂGÉE109

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!